Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1789769 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $7.22Day −0.96%Mkt cap $49M1Y −74.5%Off 52W high −78.7%Vol (1Y) 80.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,792 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest3.0% of sh out |
| Days to cover15.4d |
| 13F net flow (QoQ)−3.22% |
| Top-10 13F concentration93.2% |
| Next report (est.)2026-08-15 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$9.0M |
| Earnings (TTM)-$47.4M |
| ROE−50.4% |
| Net margin−795.9% |
| ROIC−46.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−34.4% |
| 1Y−74.5% |
| 3Y−33.9% |
| 5Y−97.8% |
| 10Y−89.4% |
| Since incept. (ann.)−19.2% |
Total return through 2026-07-29 · series begins 2016-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)80.8% |
| Ann. volatility (3Y)117.9% |
| Sharpe (1Y)−1.29 |
| Sharpe (3Y)0.42 |
| Max drawdown (1Y)−78.9% |
| Max drawdown (3Y)−92.1% |
| Beta (3Y vs SPY)2.26 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Curative Ventures V LLC | 1.9M | $16M | 28.00% | +0.0% |
| BML Capital Management, LLC | 645,600 | $5M | 9.52% | +0.0% |
| CPMG Inc | 410,922 | $3M | 6.06% | +0.0% |
| Kalehua Capital Management LLC | 322,879 | $3M | 4.76% | new |
| Vivo Capital, LLC | 292,743 | $2M | 4.32% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 174,583 | $1M | 2.57% | new |
| MILLENNIUM MANAGEMENT LLC | 132,946 | $1M | 1.96% | −45.2% |
| RENAISSANCE TECHNOLOGIES LLC | 59,100 | $486,984 | 0.87% | −12.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.62 | — | $2.2M | +0.0% |
| 2025-12-31 | 2026-03-27 | — | — | $2.2M | −19.2% |
| 2025-09-30 | 2025-11-13 | −$2.01 | — | $2.2M | +50.2% |
| 2025-06-30 | 2025-08-13 | −$3.24 | — | $2.2M | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-15 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
